Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia

Prophylaxis with recombinant factor VIII can prevent joint damage and decrease the frequency of joint and other hemorrhages in young boys with severe hemophilia A. (ClinicalTrials.gov number, NCT00207597 ClinicalTrials.gov.).